Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian "Real-Word" SAX study

• Asıl Yazarlar: Carmine D'Aniello (Yazar), Maria Giuseppa Vitale (Yazar), Azzurra Farnese (Yazar), Lorenzo Calvetti (Yazar), Maria Maddalena Laterza (Yazar), Carla Cavaliere (Yazar), Chiara Della Pepa (Yazar), Vincenza Conteduca (Yazar), Anna Crispo (Yazar), Ferdinando De Vita (Yazar), Francesco Grillone (Yazar), Enrico Ricevuto (Yazar), Michele De Tursi (Yazar), Rocco De Vivo (Yazar), Marilena Di Napoli (Yazar), Sabrina Chiara Cecere (Yazar), Gelsomina Iovane (Yazar), Alfonso Amore (Yazar), Raffaele Piscitelli (Yazar), Giuseppe Quarto (Yazar), Salvatore Pisconti (Yazar), Gennaro Ciliberto (Yazar), Piera Maiolino (Yazar), Paolo Muto (Yazar), Sisto Perdona (Yazar), Massimiliano Berretta (Yazar), Luca Galli (Yazar), Giacomo Cartenì (Yazar), Ugo De Giorgi (Yazar), Sandro Pignata (Yazar), GAETANO FACCHINI (Yazar), Sabrina Rossetti (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2016-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in s...